Lamivudine does not increase the efficacy of interferon in the treatment of mutant type chronic viral heaptitis B

Table 1 Demographic data, biochemical data and serum HBV DNA levels of patients

Patient No	Age/Gender (y)	ALT (IU/L)	Total Bilirubin (mg/dL)	Prothrombin time (INR)	HBV DNA (pg/mL)
1*	52/M	210	0.9	1.02	90
2	65/M	42	0.9	0.93	24
3	61/M	162	1.4	1.18	1924
4	43/M	38	0.8	0.91	107
5	45/M	212	0.8	1.00	303
6	34/M	49	0.4	1.02	66
7	38/M	47	0.6	1.05	262
8	36/M	119	0.9	0.81	6
9	35/M	56	0.8	0.90	7
10	48/M	154	0.5	1.12	265
11	46/M	223	1.0	1.14	56
12	38/M	290	1.8	1.16	8
13	41/M	44	1.0	0.93	8
14	39/M	195	0.7	1.03	11
15	60/M	147	0.7	1.07	17

*Patient 1 received only 8 wk of interferon therapy

Table 2 Serum ALT and HBV DNA levels of patients before, at the end, and at 6 mo after treatment

Patients	ALT (iu/L)				HBV DNA
	start	end	6 M	start	end		6 M
					LPMH	PCR	LPMH	PCR
1a	210	38	51	90	29	-	-	-
2	42	97	166	24	18	-	30	-
3	162	57	84	1924	ND	24.4	13	-
4	38	34	37	107	ND	78.8	7	-
5	212	26	66	303	ND	5.1	27	-
6	49	46	150	66	63	-	98	-
7	47	35	43	262	ND	94.7	27	-
8	119	24	20	6	ND	ND	ND	ND
9	56	80	41	7	ND	43.8	ND	93.0
10	154	54	254	265	ND	1.3	128	-
11	223	48	215	56	ND	1.2	445	-
12	290	30	24	8	ND	ND	ND	ND
13	44	22	71	8	ND	9.7	10	-
14	195	56	41	11	ND	2.2	39	-
15	147	22	47	17	ND	12.6	10	-
Mean	132	46b	90c	224	8d		63e
S.D.	71	17	58	255	12		70

ND: HBV DNA < 5 pg/mL using the liquid phase molecular hybridization assay (LPMH); HBV DNA < 20 copies/dL using the real-time polymerase chain reaction (PCR).

^aPatient 1 received only 8 wk of interferon therapy;

^bP = 0.0002,

^dP = 0.05 compared with those before treatment;

^cP = 0.058,

^eP = 0.05 compared with those at the end of treatment